Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
European Radiology|March 16, 2013
Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imagingMartina Karpitschka, Patrizia Godau-Kellner, Herbert Kellner, et al.BMC Musculoskeletal Disorders|December 20, 2013
Evaluation of the novel ultrasound score for large joints in psoriatic arthritis and ankylosing spondylitis: six month experience in daily clinical practiceValentin S Schäfer, Martin Fleck, Herbert Kellner, et al.Clinical and Experimental Rheumatology|December 7, 2021
The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with ageChristof Specker, Martin Aringer, Gerd-Rüdiger Burmester, et al.Clinical and Experimental Rheumatology|November 17, 2023
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studieMarinella Govoni, Anastas Batalov, Dimitrios T Boumpas, et al.Current Medical Research and Opinion|July 23, 2014
Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch studyRoy Fleischmann, John A Goldman, Marjatta Leirisalo-Repo, et al.BMC Musculoskeletal Disorders|July 9, 2011
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding studyRieke Alten, Juan Gomez-Reino, Patrick Durez, et al.Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.Clinical and Experimental Rheumatology|May 18, 2021
Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily careFrank Behrens, Gerd-Rüdiger Burmester, Martin Feuchtenberger, et al.Annals of the Rheumatic Diseases|September 8, 2012
The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapyTina M Backhaus, Sarah Ohrndorf, Herbert Kellner, et al.Rheumatology and Therapy|August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized TrialPhilip J Mease, Herbert Kellner, Akimichi Morita, et al.Pageof 4